Stay updated on TAPUR Study: Targeted Drug Clinical Trial
Sign up to get notified when there's something new on the TAPUR Study: Targeted Drug Clinical Trial page.

Latest updates to the TAPUR Study: Targeted Drug Clinical Trial page
- Check6 days agoChange DetectedAdded Revision: v3.5.2; Removed Revision: v3.5.0.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded multiple new study locations (e.g., Plantation, Sole Mia, Kendall, Griffin Cancer Research Building, Alex's Place, Deerfield Beach, Lennar, and Aventura) and updated corresponding contact details. The total number of locations increased from 166 to 174.SummaryDifference1%

- Check34 days agoChange DetectedAdded new contact details and principal investigator information for TAPUR study sites, including Frank Senecal, MD, and Jen Dalton, MHA, BSN, RN, with multiple locations and phone numbers. Updated the site count to 166 locations and included additional site contacts and emails.SummaryDifference1%

- Check49 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. This is a metadata update and does not affect study content or user-facing information.SummaryDifference0.0%

- Check70 days agoChange DetectedAdded arms for Dabrafenib plus Trametinib (Group 26) and Fam-trastuzumab deruxtecan-nxki (TDxD) with related mutations and drugs, expanding targeted therapy options; removed several arms (Atezolizumab+PHESGO, Pembrolizumab, Entrectinib, Larotrectinib, ROS1/NTRK groups) and updated the brain metastases exclusion, affecting eligibility and treatment choices.SummaryDifference0.8%

- Check77 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1 at the bottom of the page. This is a minor UI/text update with no impact on study information.SummaryDifference0.0%

Stay in the know with updates to TAPUR Study: Targeted Drug Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TAPUR Study: Targeted Drug Clinical Trial page.